Filing Flows

Filing Flows › Companies › Gossamer Bio › Cash flow

Gossamer Bio cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$39.4M in Q2 2026 · −$163M over twelve months

Operating cash flow−$39.4M
Free cash flow−$39.4M
Cash / net income-2.3×

Analysis

In Q2 2026, Gossamer Bio generated −$39.4M of operating cash flow. That is $7.7M more than in Q2 2025 (−$47.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$163M; the largest uses were operating cash flow ($163M); besides operations, cash came from other investing ($174M), shares issued ($1.9M); the cash balance rose by $14.8M.

Operating cash flow was −$39.4M against net income of $16.9M — -2.3× profit, less cash than reported earnings, worth checking against working capital. The largest differences: prepaid and other assets +$6.5M, payables −$4.6M, employee-related liabilities −$3.6M.

Free cash flow

Gossamer Bio: free cash flow by quarterGossamer Bio: free cash flow by quarter−$32.0MQ3 2024−$35.5MQ4 2024−$39.8MQ1 2025−$47.1MQ2 2025−$36.2MQ3 2025−$48.3MQ4 2025−$38.7MQ1 2026−$39.4MQ2 2026
Operating cash flow less capital spending.
Gossamer Bio: operating cash flow against capital spendingGossamer Bio: operating cash flow against capital spendingOperating cash flowCapital spending−$32.0M$0Q3 2024−$35.5M$0Q4 2024−$39.7M$26KQ1 2025−$47.1M$53KQ2 2025−$36.2M$0Q3 2025−$48.3M$0Q4 2025−$38.7M$0Q1 2026−$39.4M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$39.4M, Capital spending $0.

Capital allocation, year by year

Gossamer Bio: where the cash came from (up) and went (down), by fiscal yearGossamer Bio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$189MFY2021: Shares issued $2.0MFY2021: Capital spending −$1.5M$2.0MFY2021FY2022: Operating cash flow −$187MFY2022: Net borrowing −$5.8MFY2022: Shares issued $1.7MFY2022: Capital spending −$410K$1.7MFY2022FY2023: Operating cash flow −$159MFY2023: Net borrowing −$11.6MFY2023FY2024: Operating cash flow −$3.5MFY2024: Net borrowing −$12.6MFY2024FY2025: Operating cash flow −$171MFY2025: Shares issued $1.9MFY2025: Capital spending −$79K$1.9MFY2025
Over these 5 years operating cash flow totalled −$710M; the largest uses were operating cash flow ($710M) and net borrowing ($30.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$57.0M
Debtnone
Net cash$57.0M
Cash runway4 months

Gossamer Bio is burning cash: its operations consume cash, a free cash flow of −$163M a year at the current rate against $57.0M of cash and investments: a runway of about 4 months before any new financing.

Where the cash came from and went

Gossamer Bio: sources (+) and uses (−) of cash, Q2 2026Gossamer Bio: sources (+) and uses (−) of cash, Q2 2026Other investing$42.7MOperating cash flow−$39.4MOther financing−$3.1MCash drawn (+) / kept (−)−$120KExchange rates−$12K
Gossamer Bio: sources (+) and uses (−) of cash, TTM to Q2 2026Gossamer Bio: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$174MOperating cash flow−$163MCash drawn (+) / kept (−)−$14.8MShares issued$1.9MOther financing$1.3MExchange rates−$206K

From profit to cash

Gossamer Bio: net income to operating cash flow, Q2 2026Gossamer Bio: net income to operating cash flow, Q2 2026Net income$16.9MStock-based pay$2.5MReceivables$3.1MPayables−$4.6MAccrued liabilities−$1.2MEmployee-related liabilities−$3.6MDeferred revenue−$3.4MPrepaid and other assets$6.5MOperating cash flow−$39.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$39.4M——−$120K−$39.4M
Q1 2026−$38.7M—$220K−$3.3M−$38.7M
Q4 2025−$48.3M—$1.2M−$28.8M−$48.3M
Q3 2025−$36.2M—$465K$17.4M−$36.2M
Q2 2025−$47.1M−$53K$94K$2.7M−$47.1M
Q1 2025−$39.7M−$26K$132K$17.1M−$39.8M
Q4 2024−$35.5M——−$17.6M−$35.5M
Q3 2024−$32.0M——$58.4M−$32.0M

Gossamer Bio: income statement and cash flow

Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%. The chart follows the revenue to costs, profit and cash.

Gossamer Bio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.